Related Topics News -

     
 Detail   |   Print 
     
國藥太極在研生物藥「司美格魯肽」開啟全球招商
2026-05-05T  
《大行》花旗:美國禁採納中國臨床試驗數據提案通過可能性低
2026-05-04T  
美國會提案禁採納中國臨床數據
2026-05-04T  
《大行》花旗微降國藥目標價至22.6元 首季業績大致符預期
2026-04-28T  
《大行》高盛降國藥控股目標價至19.07元 料未來數季收入逐步復甦
2026-04-28T  
《大行》里昂升國藥控股目標價至25元 續予「跑贏大市」評級
2026-04-28T  
《大行》高盛對內地醫療板塊投資評級及目標價(表)
2026-04-27T  
《藍籌》國藥控股首季純利14.1億人幣 按年跌3%
2026-04-27T  
國藥控股附屬國藥股份首季賺4.74億人民幣 增長3.3%
2026-04-22T  
國藥控股附屬國藥一致首季賺2.87億人民幣 倒退12.4%
2026-04-21T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.